FibroGen
John Alden has a strong background in the legal field, with significant experience at FibroGen, Inc. where they held multiple roles over a period of ten years, including Vice President, Legal, and Director, Senior Director, Executive Director, and Corporate Counsel. Prior to joining FibroGen, Inc., they worked as an Associate at Cooley Godward Kronish LLP. John also served as a Law Clerk for the Honorable Judge Alarcon at the Ninth Circuit Court of Appeals. John Alden started their career as a Chemist I at Cardinal Health and gained business experience as a Business Intern at Senomyx, Inc.
John Alden completed their Bachelor of Science degrees in Molecular Biology and Biological Psychology at UC San Diego from 1997 to 2002. John then pursued their Juris Doctorate (JD) in Law at the University of California, Los Angeles - School of Law from 2002 to 2005.
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.